Literature DB >> 30366552

Progressive Multifocal Leukoencephalopathy.

Elena Grebenciucova1, Joseph R Berger2.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection that occurs in patients whose immune system is compromised either because of an underlying illness or an immunosuppressive medication. John Cunningham virus, prevalent in 60% or more of the adult population as a latent or persistent infection, is responsible for the syndrome of PML. This article reviews PML in association with the most common immunotherapies and discusses risk mitigation and monitoring strategies.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  John Cunningham virus; Opportunistic infection; Progressive multifocal leukoencephalopathy

Mesh:

Year:  2018        PMID: 30366552     DOI: 10.1016/j.ncl.2018.06.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  4 in total

1.  Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors.

Authors:  Chen S Tan; Joshua Ghofrani; Emma Geiger; Igor J Koralnik; Stephanie Jost
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

2.  Posterior Fossa Progressive Multifocal Leukoencephalopathy Secondary to Rituximab.

Authors:  Mounika Guduru; Venkata Sunil Bendi; Mariana S Bebawy; Dinesh Bande; Abhishek Matta
Journal:  Cureus       Date:  2020-10-10

Review 3.  Neurological Complications in Patients with Systemic Lupus Erythematosus.

Authors:  Amir Shaban; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 6.030

4.  JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies.

Authors:  Robert Bonek; Wojciech Guenter; Robert Jałowiński; Anna Karbicka; Anna Litwin; Maciej Maciejowski; Radosław Zajdel; Karolina Zajdel; Veronique Petit; Konrad Rejdak
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.